Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2013 - 2026)

Amphastar Pharmaceuticals' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $170.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 6.48% year-over-year to $170.9 million; the TTM figure through Mar 2026 stood at $170.9 million (down 6.48% YoY), while the FY2025 annual figure was $170.2 million, up 12.25% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $170.9 million, roughly flat from $170.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $266.8 million in Q3 2023, with the low at $144.3 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $172.6 million (2022), against an average of $179.5 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 69.91% in 2022, then declined 27.99% in 2024.
• Amphastar Pharmaceuticals' Cash & Equivalents stood at $156.1 million in 2022, then declined by 7.56% to $144.3 million in 2023, then rose by 5.07% to $151.6 million in 2024, then increased by 12.25% to $170.2 million in 2025, then rose by 0.45% to $170.9 million in 2026.
• Business Quant data shows AMPH's Cash & Equivalents at $170.9 million in Q1 2026, $170.2 million in Q4 2025, and $216.3 million in Q3 2025.